We will gather feedback from healthcare providers and pregnant or up to two years postpartum adult women to better understand their needs and experiences related to traumatic stress and alcohol use during pregnancy. We will conduct focus groups with maternal health and mental health professionals, as well as conduct 60-minute interviews along with a survey/questionnaire with pregnant women who are experiencing both alcohol-related challenges and trauma-related symptoms. What we learn from these conversations will help us tailor services to address the unique needs of women during pregnancy and the postpartum period.

This study is to compare the usual treatment (radiation plus temozolomide alone) to using the study treatment (usual treatment plus the study drug, vorasidenib). The addition of the study drug, vorasidenib, to the usual treatment could shrink or stabilize your cancer. The study drug is FDA (Food and Drug Administration approved. The study drug will be given orally. The study will randomize (the computer will pick the group that the participant will be enrolled in) participant to Group 1 or Group 2. Participants can expect to be on the trial for 10 years or more. There will 4 participants enrolled locally.

Patients are matched with this clinical trial based on their biomarker test results in the myeloMATCH study. This treatment trial is for adults (ages 18-59) with high-risk AML who have not started treatment yet. Doctors consider AML high risk if it has certain biomarkers that can make it harder to treat. Treatment plans for AML often involve several phases of treatment. The first phase aims to get rid of as many leukemia cells as possible. It helps make it easier for further treatment to keep the cancer under control. Usually, the first treatment patients receive for AML is a combination of 2 chemotherapy drugs, daunorubicin and cytarabine. The purpose of this study is to learn if other options for first treatment may work better for people with high-risk AML. The study doctors will test 4 new treatments and compare them to the usual chemotherapy. This is important because knowing AML is high-risk gives doctors more information about the cancer and how to treat it. People with high-risk AML may benefit from a different approach to treatment. Improving options for people in the first phase of treatment could make further phases of treatment more successful.

This study is for patients diagnosed with early-stage melanoma and are the age of 75 or older. The usual approach for patients who are not in a study is treatment with two surgical procedures, a wide local excision (WLE) plus a sentinel lymph node (SLN) biopsy, followed by immunotherapy. The purpose of this study is to find if performing the WLE alone is just as effective as the usual approach and if it leads to improvements in patients' overall well-being.

A wide local excision (A wide local excision (WLE) is a surgical procedure performed to cut out an abnormal lesion and some surrounding normal tissue; this is sometimes followed by a sentinel lymph node (SLN) biopsy, in which lymph nodes that cancer cells could spread to are removed as well. Immunotherapy is a type of cancer treatment that uses your body's immune system to identify and attack cancer cells.

Patients may participate in this study for up to 5 years. Procedures include a surgical biopsy, surveys, and regular visits with your doctor including follow-up study visits or phone calls every 6 months. There will be about 428 people taking part in this study, approximately 39 participants will be enrolled at MUSC.

Risks include infection, scarring, and bleeding. Participants may or may not receive a direct benefit from participating in this trial, however, information learned from the trial may help other people in the future.

The purpose of this study is to evaluate investigational treatments (study drug) for locally advanced/metastatic colorectal cancer. This study seeks to see if Fruquintinib in combination with TAS-102 improves overall survival when compared to Fruquintinib alone.The goal is to determine the optimal dose level, safety, and tolerability for the study drug.Treatment for this study may be up to 3 years. The procedures include blood and urine samples, questionnaires, infusions, and CT scans. Risks include high blood pressure, diarrhea, vomiting, reduced appetite, weight loss, hoarse voice, joint pain, and weakness. You may or may not receive a direct benefit from participating in this trial, however, information learned from the trial may help other people in the future.

This study is for patients that have been diagnosed with squamous cell, adenocarcinoma, or adenosquamous cervical cancer. This study is testing an investigational drug called pembrolizumab. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). A computer will be used to assign you to one of the study groups. This process is called "randomization." Like flipping a coin, everyone has an equal chance of being placed in any group. The primary purpose of this study is to determine whether induction immunotherapy (IO) and chemotherapy prior to concurrent chemoradiotherapy plus immunotherapy (CCRT+IO) improves progression-free survival (PFS) compared to CCRT+IO alone. The study drug is given by infusion. Participants in this study can expect to be on the study for 7 years.

This study is for participants with symptoms of mast cell activation (SMAC). The primary purpose of this study is to learn about clonal mast cell diseases. Clonal mast cell diseases are hard to diagnose because symptoms are not specific, and they can overlap with other diseases. The tools currently used by doctors to look for clonal mast cell diseases in the blood may not identify all patients. This study is being done to develop an investigational blood test that looks for a change in a gene called KIT. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). Two types of blood tests will be compared against each other. Participants in this study can expect to be in this study for about 6 months.

This study is for patients diagnosed with recurrent/persistent PD-LI enriched squamous cell carcinoma of the head and neck and undergoing salvage surgery. The purpose of this study is to compare the usual treatment of surgery alone, to using chemotherapy (cisplatin and paclitaxel) or chemo-immunotherapy [carboplatin and paclitaxel with cemiplimab (REGN2810)] plus the usual treatment.

Carboplatin, cisplatin, paclitaxel, and cemiplimab are FDA approved to treat head and neck cancers. This study seeks to answer if adding chemotherapy or chemo-immunotherapy before surgery extends the length of time without your cancer returning compared to the surgery alone.

Patients may participate in this study for up to 3 years. Procedures surgery, blood tests, chemotherapy, and regular visits with your doctor including follow-up study visits or phone calls every 3 months. There will be about 180 people taking part in this study, approximately x participants will be enrolled at MUSC.

Risks include hair loss, diarrhea, nausea, vomiting, anemia, infection, and fever. Participants may or may not receive a direct benefit from participating in this trial, however, information learned from the trial may help other people in the future.

This study is for patients that have been diagnosed with diagnosed with unresectable, locally advanced, recurrent or metastatic renal cell carcinoma (RCC). The study is testing investigational drugs called pumitamig."Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). The main purpose of this study is to evaluate the safety and tolerability, and to determine the recommended phase 2 dose (RP2D), of pumitamig administered in combination with ipilimumab or cabozantinib. The study drug is given by infusion. Participants in this study can expect to be in this study for about 4 years.

This is a descriptive study designed to determine the proportion of women who are sexually active after minimally invasive sacrocolpopexy, with particular focus on those aged 65 and older. Because sacrocolpopexy carries certain risks—especially in older women—but also preserves vaginal length and may improve sexual function, understanding post-surgical sexual activity can help clinicians counsel patients when choosing between reconstructive surgeries, which preserve vaginal length, and obliterative surgeries, which do not. The study also aims to better understand patient values in surgical decision-making related to sexual activity. Women who had sacrocolpopexy at MUSC since January 1, 2015 will be contacted to complete two questionnaires: one assessing sexual activity and satisfaction with surgery, and one assessing sexual function using an adapted PISQ-IR questionnaire. Data will be analyzed using descriptive and comparative statistics to examine the proportion of sexually active women in groups under 65 versus 65 and older, as well as to compare their sexual function outcomes.